阅读说明：本技术 一种生长激素原料药溶液、水针剂及其制备方法 (Growth hormone raw material medicine solution, water injection and preparation method thereof ) 是由 朱琪 上官春晓 王云 陈晓春 于 2020-03-23 设计创作，主要内容包括：本发明涉及一种生长激素原料药溶液,包括生长激素,所述的生长激素原料药溶液还包括缓冲液,所述的缓冲液中包括8.3～9.1g/L的氯化钠、9.5～10.5mM的柠檬酸钠,所述的缓冲液的pH为5.7～6.3。本发明的原料药溶液可以在冷冻状态下稳定保存和运输,且可在复溶后保持产品的纯度和质量,且本发明的制备方法方便、节能、高效,适合工业化生产。(The invention relates to a growth hormone bulk drug solution which comprises growth hormone and a buffer solution, wherein the buffer solution comprises 8.3-9.1 g/L of sodium chloride and 9.5-10.5 mM of sodium citrate, and the pH value of the buffer solution is 5.7-6.3. The bulk drug solution can be stably stored and transported in a frozen state, the purity and the quality of the product can be kept after redissolution, and the preparation method is convenient, energy-saving and efficient, and is suitable for industrial production.)

1. A growth hormone bulk drug solution comprises growth hormone, and is characterized in that: the growth hormone bulk drug solution further comprises a buffer solution, wherein the buffer solution comprises 8.3-9.1 g/L of sodium chloride and 9.5-10.5 mM of sodium citrate, and the pH value of the buffer solution is 5.7-6.3.

2. The growth hormone bulk drug solution of claim 1, wherein: the buffer solution also comprises 1.9-2.1 g/L of Tween 20.

3. A growth hormone bulk drug solution according to claim 1 or 2 wherein: the concentration of the growth hormone is 6-10 g/L.

4. A growth hormone bulk drug solution according to claim 1 or 2 wherein: the growth hormone is one or more of recombinant human growth hormone, recombinant bovine growth hormone and recombinant porcine growth hormone.

5. The growth hormone bulk drug solution of claim 1, wherein: the buffer solution comprises 8.7g/L of sodium chloride and 10mM of sodium citrate; or the components of the buffer solution are 8.7g/L of sodium chloride, 10mM of sodium citrate and 2g/L of Tween 20.

6. A method of preparing a solution of growth hormone drug substance as claimed in any one of claims 1 to 5, characterized in that: and adding the growth hormone into the buffer solution to prepare the growth hormone bulk drug solution.

7. The method of claim 6, wherein: after the growth hormone is added into the buffer solution, the concentration of the growth hormone is concentrated to 7-8g/L through ultrafiltration, and then the buffer solution is used for diluting the concentration of the growth hormone to 6.2-6.8 g/L.

8. A method of storing a solution of growth hormone drug substance according to any of claims 1 to 5, characterized in that: and (3) freezing and storing the growth hormone raw material medicine solution.

9. The storage method according to claim 8, wherein: the freezing temperature is-15 ℃ or below.

10. Use of a growth hormone drug substance solution as claimed in any one of claims 1 to 5 or a cryopreserved drug substance solution as claimed in claim 8 or 9 in the preparation of a growth hormone water injection.

11. A preparation method of growth hormone water injection is characterized in that: the method comprises the following steps:

(1) thawing the frozen growth hormone bulk drug solution of claim 8 or 9, or taking the growth hormone bulk drug solution of any one of claims 1 to 5;

(2) adding a sodium chloride-citrate solution containing 95-105 g/L of tween, and uniformly stirring;

(3) adding a sodium chloride-citrate solution containing phenol with the concentration of less than or equal to 15g/L, and uniformly stirring;

(4) optionally, a sodium chloride-citrate solution is used to adjust the concentration of growth hormone to the desired concentration.

Technical Field

The invention belongs to the technical field of gene recombination, and particularly relates to a growth hormone bulk drug solution, a water injection and a preparation method thereof.

Background

The recombinant human growth hormone is a gene engineering medicine prepared by a gene engineering method, has a protein sequence and a structure which are completely consistent with those of the human growth hormone secreted by eosinophilic cells of the anterior pituitary of a natural human, contains 191 amino acids, and is a non-glycosylated single-chain water-soluble protein. The human growth hormone has wide action, plays a role in promoting growth of most tissues (except nerve tissues) of a human body, can promote the degradation of fat and sugar, and enhances the synthesis of protein and nucleic acid.

The recombinant human growth hormone can be used for treating short stature and growth and development retardation of children traditionally, and can promote the height of teenagers to increase by 5-10cm every year, so that children lack of the growth hormone can obtain better adult height, and the recombinant human growth hormone is safe and effective. It can also be used for treating adult growth hormone deficiency, such as growth hormone deficiency caused by pituitary operation, anterior pituitary hypofunction, head trauma, infection or cerebral radiotherapy, obesity, abdominal fat accumulation, muscle volume reduction, asthenia, memory deterioration, osteoporosis, and emotional depression. The above symptoms can be corrected by administering appropriate amount of recombinant human growth hormone, such as reducing fat accumulation in abdomen, increasing muscle content in body, and reducing risk of cardiovascular diseases. The long-term administration can also improve self-sensation and enhance emotion, thereby comprehensively improving the physical and mental health level of patients. In addition, the recombinant human growth hormone can be used for adjuvant treatment of burn, fracture, wound, hemorrhagic ulcer, tissue necrosis, muscular atrophy, osteoporosis, obesity, etc. The clinical use of growth hormone in cosmetics and anti-aging is also under constant development.

Since the first approval of recombinant human growth hormone by FDA in the united states for clinical use in 1985, the global demand and sales of recombinant human growth hormone have been the top list of genetically engineered drugs. At present, recombinant human growth hormone has been loaded into the multinational pharmacopoeia, and annual income of sale is more than $ 30 billion in the world. The growth hormone which is sold on the market in the world comprises two types of powder injection and water injection. The powder injection preparation process needs to add excipient and is subjected to freeze drying treatment, so that polymers and high polymers are easily formed, the systemic or local immune reaction is caused clinically, the drug effect is reduced, side effects are brought, and the long-term use by patients is not facilitated. And the powder injection needs to be redissolved and uniformly mixed, and the turbidity is formed by improper mixing, so that the taking and absorption of the medicine are influenced, the space structure damage of the medicine is further increased, more polymers are formed, and the powder injection is inconvenient to use and inaccurate in dosage for patients. In addition, the volume ratio of the added inactive ingredients and excipients in the freeze-drying and redissolution is high, so that the injection volume of a patient is larger than that of a water injection, the inconvenience of injection administration is increased, and local adverse reactions at the injection part are more easily caused. Clinical data at home and abroad show that the water injection has extremely low immunogenic reaction rate, can reduce the level of anti-drug antibodies of patients caused by using freeze-dried preparations, and is safer after long-term use.

The international main stream product of the recombinant human growth hormone is a water injection preparation, and most of the existing recombinant human growth hormone products in China are freeze-dried powder injections. The development of a stable water injection production process suitable for commercial large-scale production has important significance for promoting the successful marketing of recombinant human growth hormone products. The conventional growth hormone injection solution is prepared by exposing the components, process and storage conditions of the solution of the raw materials, or by preparing the raw materials into solution of the same components, and storing at 2-8 deg.C (such as U.S. Pat. No. 5,5763394,5981485,6448225). However, after the production of the raw material medicine is finished, each detection, especially the microbial detection, needs 2-3 weeks, if the preparation is carried out before the detection result of the raw material medicine is finished, certain risks exist, the preparation is already close to the storage life of the raw material medicine after the detection of the raw material medicine is released, and the bulk solution of the raw material medicine is inconvenient to store and transport, so that the raw material medicine produced and stored in the mode is used for preparing the preparation, which is not beneficial to ensuring higher quality of preparation products and is also not beneficial to convenient industrial production. Therefore, there is a need for a method for producing injectable formulations of growth hormone that is easier and more convenient and that can extend the shelf life of the drug substance.

Disclosure of Invention

The invention aims to solve the technical problem of providing a growth hormone raw material medicine solution and a water injection capable of prolonging the preservation period of raw material medicines and a preparation method thereof.

The inventor finds that the reason why the growth hormone water injection needs to be stored at 2-8 ℃ is mainly due to the fact that once the water injection is frozen and thawed, severe turbidity can occur, precipitates can be formed, the content of dimers and high polymers is increased, and the purity of products is reduced. In order to solve the problems, the inventor researches the cause of turbidity generated after freeze thawing of the growth hormone water injection, discovers an effective cryopreserved growth hormone raw material medicine, and solves the problem of cryopreservation of the growth hormone raw material medicine. The growth hormone water injection prepared by the method not only has the same product quality and stability as the growth hormone water injection prepared by the conventional non-cryopreserved raw material medicine, but also can be stably stored for 2 years at the temperature of minus 20 ℃, and the stability is superior to that of the conventional non-cryopreserved raw material medicine.

In order to solve the technical problems, the invention adopts the following technical scheme:

the growth hormone raw material solution also comprises a buffer solution, wherein the buffer solution comprises 8.3-9.1 g/L of sodium chloride and 9.5-10.5 mM of sodium citrate, and the pH value of the buffer solution is 5.7-6.3.

The buffer solution does not contain phenol, and if the buffer solution contains phenol, the raw material medicine solution is turbid after freeze thawing.

According to one embodiment, the buffer solution further comprises 1.9-2.1 g/L of Tween 20.

Preferably, the concentration of the growth hormone is 6-10 g/L.

Preferably, the growth hormone is one or more of recombinant human growth hormone, recombinant bovine growth hormone and recombinant porcine growth hormone.

According to a particular and preferred embodiment, the buffer has a composition of 8.7g/L sodium chloride and 10mM sodium citrate.

According to another specific and preferred embodiment, the buffer consists of 8.7g/L of sodium chloride, 10mM of sodium citrate and 2g/L of Tween 20.

In another aspect, the invention provides a method for preparing the solution of growth hormone raw material, wherein the growth hormone raw material solution is prepared by adding the growth hormone into the buffer solution.

Preferably, after the growth hormone is added into the buffer solution, the concentration of the growth hormone is concentrated to 7-8g/L through ultrafiltration, and then the buffer solution is used for diluting the concentration of the growth hormone to 6.2-6.8 g/L.

Preferably, the growth hormone can be obtained by fermentation expression of escherichia coli, yeast or mammalian cells and the like, collection, separation, crude purification and fine purification. The specific preparation method of the growth hormone can be realized by adopting the conventional method in the field.

The purified growth hormone is replaced into the buffer solution to prepare the liquid bulk drug, so that the liquid bulk drug can be stably stored and transported in a frozen state, the purity and the quality of the product can be kept after redissolution, the liquid bulk drug is melted before production, and the preservative is added, mixed uniformly and subpackaged into the liquid preparation.

The third aspect of the present invention provides a method for storing the solution of growth hormone drug substance, wherein the solution of growth hormone drug substance is frozen.

Preferably, the freezing temperature is-15 ℃ or below.

The fourth aspect of the invention provides an application of the growth hormone raw material solution or the frozen raw material solution in preparing a growth hormone water injection.

The fifth aspect of the invention provides a preparation method of a growth hormone water injection, which comprises the following steps:

(1) melting the growth hormone bulk drug solution frozen by the storage method, or taking the growth hormone bulk drug solution;

(2) adding a sodium chloride-citrate solution containing 95-105 g/L of tween, and uniformly stirring;

(3) adding a sodium chloride-citrate solution containing phenol with the concentration of less than or equal to 15g/L, and uniformly stirring;

(4) optionally, a sodium chloride-citrate solution is used to adjust the concentration of growth hormone to the desired concentration.

Preferably, the sodium chloride-citrate solution is the same buffer as the bulk drug is prepared.

In the present invention, the concentration of growth hormone in the injection solution of growth hormone is adjusted according to specific specifications, for example, 5.0 g/L.

The water injection is preserved at the temperature of 2-8 ℃.

Due to the implementation of the technical scheme, compared with the prior art, the invention has the following advantages:

the bulk drug solution can be stably stored and transported in a frozen state, the purity and the quality of the product can be kept after redissolution, and the preparation method is convenient, energy-saving and efficient, and is suitable for industrial production.

Drawings

Fig. 1 is a graph of the results of size exclusion chromatography (SE C-HPLC) purity analysis of the recombinant human growth hormone drug substance and formulation of example 7, wherein the upper curve is 99.93% pure recombinant human growth hormone drug substance, the lower curve is 99.75% pure recombinant human growth hormone formulation, the peak labeled 1 is recombinant human growth hormone, the peak labeled 2 is sodium citrate, and the peak labeled 3 is phenol.

Detailed Description

The present invention will be described in further detail with reference to specific examples, but the present invention is not limited to the following examples. The implementation conditions adopted in the embodiments can be further adjusted according to different requirements of specific use, and the implementation conditions not mentioned are conventional conditions in the industry.

The technical scheme of the invention is described by taking the recombinant human growth hormone as an example, and the process and components of the invention are also applicable to other types of recombinant growth hormones, such as recombinant bovine growth hormone, recombinant porcine growth hormone and the like.

Example 1

The recombinant human growth hormone is expressed by fermentation of escherichia coli, and the recombinant human growth hormone with the purity not lower than 96% is obtained through collection, separation, coarse purification and fine purification.

The purified recombinant human growth hormone was taken and replaced into a buffer containing 8.7g/L sodium chloride, 10mM sodium citrate, 2.0g/L Tween 20, pH6.0, so that the final protein concentrations were 6.0g/L, 7.5g/L and 10.0g/L, respectively. Freezing the protein solution with each concentration at-20 deg.C, thawing at room temperature, repeating for 5 times, sampling after each thawing, and detecting with clarity and size exclusion chromatography (SE C-HPLC), wherein the clarity detection is visual method.

The clarity detection results of the bulk drugs with different freezing and thawing times are shown in table 1, and the results can be known from table 1: the clarity of the buffer solution is unchanged after 5 times of freeze thawing in 8.7g/L sodium chloride, 10mM sodium citrate, 2.0g/L Tween 20 and pH6.0 buffer solution, and the buffer solution is between 0 and 0.5 grade, which indicates that the buffer solution is suitable for being used as a recombinant human growth hormone liquid bulk drug buffer solution and can tolerate 5 times of freeze thawing.

TABLE 1

The results of the size exclusion chromatography for detecting the purity of the crude drug with different freezing and thawing times are shown in table 2, and the results of the size exclusion chromatography show that the crude drug can tolerate 5 times of freezing and thawing in 8.7g/L sodium chloride, 10mM sodium citrate, 2.0g/L Tween 20 and pH6.0 buffer solution (buffer solution 1), and the dimer is not increased obviously. The buffer solution is suitable for being used as a recombinant human growth hormone liquid bulk drug buffer solution and can tolerate 5 times of freeze thawing.

TABLE 2

Example 2

The recombinant human growth hormone protein precursor is expressed by fermentation of escherichia coli, and the recombinant human growth hormone with the purity not lower than 96% is obtained through collection, separation, coarse purification and fine purification.

Purified recombinant human growth hormone was taken and replaced in buffer (buffer 2) containing 8.7g/L sodium chloride, 10mM sodium citrate, 2.5g/L phenol, pH6.0 to give final protein concentrations of 6.0g/L, 7.5g/L and 10.0g/L, respectively. And (3) respectively freezing the protein solutions with the concentrations at-20 ℃, taking out the frozen protein solutions after freezing and thawing the frozen protein solutions at room temperature, repeating the steps for 5 times, and sampling the protein solutions after each thawing for clarity and molecular exclusion chromatography detection.

According to the clarity detection result, turbidity is generated after 1 freezing and thawing in 8.7g/L sodium chloride, 10mM sodium citrate and 2.5g/L phenol, and the buffer solution is not suitable for being used as a storage solution of liquid bulk drugs.

Example 3

The recombinant human growth hormone protein precursor is expressed by fermentation of escherichia coli, and the recombinant human growth hormone with the purity not lower than 96% is obtained through collection, separation, coarse purification and fine purification.

Purified recombinant human growth hormone was taken and replaced in a buffer (buffer 3) containing 8.7g/L sodium chloride, 10mM sodium citrate, pH6.0 to give final protein concentrations of 6.0g/L, 7.5g/L and 10.0g/L, respectively. And (3) respectively freezing the protein solutions with the concentrations at-20 ℃, taking out the frozen protein solutions after freezing and thawing the frozen protein solutions at room temperature, repeating the steps for 5 times, and sampling the protein solutions after each thawing for clarity and molecular exclusion chromatography detection.

The clarity detection results of the bulk drugs with different freeze thawing times are shown in table 3, and it can be known from table 3 that: the clarity remained unchanged between 0.5 and I stages after 5 freeze-thawing in 8.7g/L sodium chloride, 10mM sodium citrate, pH6.0 buffer. The buffer solution is suitable for being used as a recombinant human growth hormone liquid bulk drug buffer solution and can tolerate 5 times of freeze thawing.

The results of the size exclusion chromatography for detecting the purity of the raw material medicines with different freezing and thawing times are shown in table 4, and the results of the size exclusion chromatography can be known as follows: the dimer is not increased obviously after 5 times of freeze thawing in 8.7g/L sodium chloride, 10mM sodium citrate and pH6.0 buffer solution, which indicates that the buffer solution is suitable for being used as the liquid bulk drug buffer solution of the recombinant human growth hormone and can tolerate 5 times of freeze thawing.

TABLE 3

TABLE 4

Example 4

The recombinant human growth hormone bulk drug solution was prepared as in example 3, the protein concentrations were adjusted to 5.56g/L, 6.0g/L, 7.5g/L and 10.0g/L, respectively, and the clarity was checked by sampling. Tween 20 was added to a buffer solution of 8.7g/L sodium chloride, 10mM sodium citrate, pH6.0 to prepare a Tween 20 solution diluted to 4g/L, 6g/L,12g/L, 20 g/L. Phenol is respectively added into the Tween 20 solution to respectively prepare phenol/Tween 20 solutions with the phenol concentrations of 5g/L, 7.5g/L, 15g/L and 25 g/L. Adding the phenol/Tween 20 solution with required concentration into the growth hormone solution with each concentration, stirring and mixing uniformly to prepare the recombinant human growth hormone water injection, wherein the final concentrations of the growth hormone, the Tween 20 and the phenol are respectively 5.0g/L, 2.0g/L and 2.5g/L, and sampling for clarity detection.

The results of the clarity tests are shown in Table 5, and it can be seen from the results of the clarity tests that when the phenol/Tween 20 solution is prepared, turbidity is generated when the phenol concentration is more than 15g/L, and the turbidity increases with the increase of the phenol concentration, and then the phenol/Tween 20 solution is added into the growth hormone solution, the turbidity is reduced and the clarity can be recovered after filtration, but the turbidity may affect the quality of the growth hormone, which leads to the reduction of the purity, therefore, the phenol concentration in the phenol/Tween 20 should not be higher than 15 g/L.

TABLE 5

The results of size exclusion chromatography are shown in Table 6, and it is clear from the results of size exclusion chromatography that the phenol concentration is 15g/L or less, the purity is substantially the same before and after addition, and when the phenol concentration is 25g/L, the purity is slightly reduced.

TABLE 6

Example 5

The recombinant human growth hormone bulk drug solution was prepared as in example 3, the protein concentrations were adjusted to 5.56g/L, 5.80g/L, 6.00g/L, 6.12g/L and 7.5g/L, respectively, and the clarity was checked by sampling. Tween 20 was added to a buffer solution of 8.7g/L sodium chloride, 10mM sodium citrate, pH6.0 to prepare a 100g/L Tween 20 solution. Phenol was added to 8.7g/L sodium chloride, 10mM sodium citrate, pH6.0 buffer to prepare phenol solutions having concentrations of 7.5g/L, 15g/L, 16.7g/L, 20.8g/L and 25g/L, respectively.

Adding 100g/L Tween 20 solution into growth hormone solution of each concentration, stirring and mixing. Then respectively adding phenol solutions with different concentrations, stirring and mixing uniformly to prepare the recombinant human growth hormone water injection, wherein the final concentrations of the growth hormone, the Tween 20 and the phenol are respectively 5.0g/L, 2.0g/L and 2.5g/L, and sampling for clarity detection and molecular exclusion chromatography analysis.

The results of size exclusion chromatography are shown in Table 7, where there was essentially no change in purity when a buffer containing 7.5g/L phenol was added, with a slight decrease in purity to 15g/L and a further decrease in purity with increasing concentration of phenol added.

TABLE 7

Example 6

The recombinant human growth hormone solution obtained after chromatography purification is replaced into 8.7g/L sodium chloride, 10mM sodium citrate and pH6.0 buffer solution by ultrafiltration, concentrated to 7-8g/L, then diluted to 6.5g/L by 8.7g/L sodium chloride, 10mM sodium citrate and pH6.0 buffer solution, filtered by 0.22 mu m, and then subpackaged into 5mL penicillin bottles for freezing storage at-20 ℃.

Taking out the frozen growth hormone bulk drug solution from-20 ℃, respectively melting in an ice-water mixture at 2-8 ℃ and 30 ℃, and recording the time required for complete melting. The sample is taken for clarity and purity analysis, the analysis results are shown in table 8 (time required for melting the raw material drug under different conditions, clarity and purity of molecular exclusion chromatography), and the results show that the influence of the melting temperature of the raw material drug on the clarity and purity is not obvious.

TABLE 8

Example 7

The recombinant human growth hormone bulk drug solution was prepared as in example 6, aseptically filtered, and then dispensed into 1L cryopreservation bottles, 0.5L/bottle, and stored at-20 ℃. Sampling and detecting the clarity, the purity of the molecular exclusion chromatography and the like. The clarity is 0-0.5 by detection, other indexes all meet pharmacopeia requirements, and the purity analysis result is shown in figure 1.

Tween 20 was added to a buffer solution of 8.7g/L sodium chloride, 10mM sodium citrate, pH6.0 to prepare a 100g/L Tween 20 solution. Phenol was added to 8.7g/L sodium chloride, 10mM sodium citrate, pH6.0 buffer to prepare a 15g/L phenol solution.

Freezing the solution of the growth hormone raw material medicine at-20 ℃, taking out, and completely melting the solution at 2-8 ℃ (about 36 hours); adding 100g/L of Tween 20 solution respectively, and stirring and mixing uniformly at 200-300 rpm; then adding a phenol solution, and uniformly stirring at 200-300 rpm; finally, the concentration of the growth hormone is diluted to 5.0g/L by using 8.7g/L sodium chloride, 10mM sodium citrate and a buffer solution with pH of 6.0 to prepare a recombinant human growth hormone water injection, wherein the final concentrations of the growth hormone, the Tween 20 and the phenol are 5.0g/L, 2.0g/L and 2.5g/L respectively. Sampling and carrying out various detections such as clarity detection, molecular exclusion chromatography purity and the like. The clarity is 0-0.5 by detection, other indexes all meet pharmacopeia requirements, and the purity analysis result is shown in figure 1.

Example 8

The recombinant human growth hormone bulk drug solution was prepared as in example 6, and subjected to stability studies at-20. + -. 5 ℃ and 5. + -. 3 ℃ respectively. And detecting the changes of the clarity, the high molecular weight protein and the related protein content of the recombinant human growth hormone raw material medicine stock solution under different storage conditions by using a visual observation method, a molecular exclusion chromatography and a reversed-phase high performance liquid chromatography. The stability data obtained at-20 + -5 deg.C and 5 + -3 deg.C are shown in Table 9 (crude drug stability data at-20 + -5 deg.C) and Table 10 (crude drug stability data at 5 + -3 deg.C). The stability data shows that the recombinant human growth hormone raw material liquid can be stably stored for 24 months at the temperature of minus 20 +/-5 ℃ and can be stably stored for 1 month at the temperature of 5 +/-3 ℃.

TABLE 9

Watch 10

Time point of 5 + -3 deg.C (moon)	Acceptance criteria	0	1	3	6	12
							Clarity of the product	Clear or slightly turbid	Clarification	Clarification	Clarification	Clarification	Clarification
High molecular weight protein content (%)	≤4.0	0.1	0.2	0.4	0.5	0.5
							Content of related protein (%)	≤6.0	2.4	3.1	5.6	6.5	6.4

A recombinant human growth hormone injection solution was prepared as in example 7, and was subjected to stability examination at 5. + -. 3 ℃ and 25. + -. 2 ℃. The change of the clarity, the content of high molecular weight protein and related protein of the recombinant human growth hormone preparation under different storage conditions is detected by a visual observation method, a molecular exclusion chromatography method and a reversed-phase high performance liquid chromatography method. The stability data obtained at 5 + -3 deg.C and 25 + -2 deg.C are shown in Table 11 (stability data at 5 + -3 deg.C) and Table 12 (stability data at 25 + -2 deg.C), respectively, and the stability data shows that the recombinant human growth hormone preparation can be stably stored at 5 + -3 deg.C for 24 months and at 25 + -2 deg.C for 1 month.

TABLE 11

TABLE 12

According to the invention, through the examination of the freeze-thaw stability of the recombinant human growth hormone raw material medicines in different solutions, the recombinant human growth hormone raw material medicine capable of tolerating freeze-thaw is determined, and the components of the recombinant human growth hormone raw material medicine are 6.5 +/-0.3 g/L of recombinant human growth hormone, 8.7g/L of sodium chloride, 10mM of sodium citrate, pH6.0 or 6.5g/L of recombinant human growth hormone, 8.7g/L of sodium chloride, 10mM of sodium citrate, 2.0g/L of Tween 20 and pH6.0. The bulk drug solution prepared by the conventional preparation method needs to be stored at 2-8 ℃ and needs to be used for preparation production within 1 month, the recombinant human growth hormone bulk drug solution prepared by the method can be stably stored at-20 ℃ with the stability reaching 2 years, and the recombinant human growth hormone water injection is prepared by the process of the invention after the bulk drug solution is further melted, so that the product quality can meet the quality indexes and stability requirements of European, American and Chinese pharmacopoeias.

The present invention has been described in detail in order to enable those skilled in the art to understand the invention and to practice it, and it is not intended to limit the scope of the invention, and all equivalent changes and modifications made according to the spirit of the present invention should be covered by the present invention.